Methicillin-Resistant Staphyloccocus Aureus (MRSA) | Unmet Need | Bone and Joint infections | US/EU | 2017
Adult OM/PJI due to MRSA are among the most hard-to-treat MRSA infections due to the difficulties for the body’s natural infection-fighting cells and antibiotics to reach the infected tissues in the bones. However, there is no guidance published by the FDA or the EMA to help drug developers to design clinical trials testing antibiotics for OM/PJI. Indeed, no new antibiotic has been approved for the treatment of OM/PJI by the FDA or EMA in the last two decade, and only a few clinical trials have been conducted to evaluate antibiotics’ efficacy and safety/tolerability for OM/PJI. The lack of approved labels and the paucity of relevant clinical efficacy and safety data force managing physicians to rely on their own experience to select antibiotics for a protracted therapy required for adult OM/PJI due to MRSA, representing a significant unmet need in this field.
Questions answered:
- What are the treatment drivers and goals for adult OM/PJI due to MRSA?
- What attributes are key influencers, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for adult OM/PJI due to MRSA?
- What are the prevailing areas of unmet need and opportunity in adult OM/PJI due to MRSA?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European ID specialists for a hypothetical new drug for adult OM/PJI due to MRSA?
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 31 European ID specialists fielded in January 2017
Key companies: Allergan, Cempra, Merck, Pfizer
Key drugs: vancomycin, daptomycin, dalbavancin, linezolid, ceftaroline, Taksta, rifampin, TMP/SMX
